| Literature DB >> 30314503 |
Young Jae Ryu1, Jin Seong Cho1, Jung Han Yoon1, Min Ho Park2.
Abstract
BACKGROUND: Papillary thyroid cancer (PTC) patients with ipsilateral neck metastatic lymph node (LN) and those with contralateral neck metastatic LN belong to N1b. Only a few studies have reported on comparisons with regard to laterality of metastatic lateral LN. The aim of this study was to evaluate predictive factors for contralateral neck LN metastasis and to determine prognostic factors for recurrence in PTC patients with N1b.Entities:
Keywords: Modified radical neck dissection; Papillary thyroid cancer; Recurrence
Mesh:
Year: 2018 PMID: 30314503 PMCID: PMC6186061 DOI: 10.1186/s12957-018-1496-1
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
Patients’ demographics
| Variables | Number (%) |
|---|---|
| Age (years)§ | 46 (17–80) |
| ≤ 55 years | 285 (73.1) |
| Male | 118 (30.3) |
| Hypertension | 62 (15.9) |
| Diabetes | 26 (6.7) |
| Modified radical neck dissection | |
| Ipsilateral | 346 (88.7) |
| Bilateral | 44 (11.3) |
| Main tumor size (cm)* | 1.61 ± 0.97 |
| > 2 cm | 93 (23.8) |
| T stage | |
| T1a | 121 (31.0) |
| T1b | 109 (27.9) |
| T2 | 40 (10.3) |
| T3a | 4 (1.0) |
| T3b | 52 (13.3) |
| T4a | 64 (16.4) |
| Multifocality | 142 (36.4) |
| Bilaterality | 125 (32.1) |
| Extrathyroidal extension | |
| No | 199 (51.0) |
| Minor | 75 (19.2) |
| Gross | 116 (29.7) |
| Number of central lymph node | |
| Harvested§, * | 6 (2–65), 7.4 ± 6.0 |
| Metastatic§, * | 3 (0–29), 3.8 ± 4.0 |
| Number of lateral lymph node | |
| Harvested§, * | 16 (8–62), 18.6 ± 10.3 |
| Metastatic§, * | 4 (1–23), 4.9 ± 3.9 |
| Skip metastases | 86 (22.1) |
| Stage | |
| I | 285 (73.1) |
| II | 79 (20.3) |
| III | 26 (6.7) |
| Lymphovascular invasion | 20 (5.1) |
| Chronic lymphocytic thyroiditis | 100 (25.6) |
| Recurrence | 84 (21.5) |
| Follow-up§ | 81 months (6–156) |
| Total patients | 390 |
§Median and range
*Mean and standard deviation
Distribution of recurrence site
| Number | |
|---|---|
| Central LN or operative bed | 33 |
| Only central LN or op bed | 19 |
| + Lateral LN | 12 |
| + Distant metastasis | 1 |
| + Lateral LN + distant metastasis | 1 |
| Only lateral LN | 48 |
| Only distant metastasis | 3 |
LN lymph node
Comparison of MRND type and clinicopathologic characteristics
| Variables | Ipsilateral MRND | Bilateral MRND |
|
|---|---|---|---|
| Age | 46.2 ± 13.3 | 48.1 ± 15.6 | 0.369 |
| ≤ 55 years | 255 (73.7) | 30 (68.2) | 0.471 |
| > 55 years | 91 (26.3) | 14 (31.8) | |
| Sex | < 0.001 | ||
| Female | 252 (72.8) | 20 (45.5) | |
| Male | 94 (27.2) | 24 (54.5) | |
| Main tumor size (cm) | 1.54 ± 0.91 | 2.20 ± 1.21 | < 0.001 |
| ≤ 2 cm | 272 (78.6) | 25 (56.8) | 0.002 |
| > 2 cm | 74 (21.4) | 19 (43.2) | |
| Number of central lymph node | |||
| Harvested | 7.2 ± 5.9 | 8.4 ± 6.2 | 0.210 |
| Metastatic | 3.4 ± 3.5 | 6.3 ± 6.0 | < 0.001 |
| Number of lateral lymph node | < 0.001 | ||
| Harvested | 16.6 ± 8.1 | 33.6 ± 13.3 | < 0.001 |
| Metastatic | 4.2 ± 2.9 | 10.5 ± 5.5 | |
| Skip metastases | 80 (23.1) | 6 (13.6) | 0.179 |
| LN ratio | 0.34 ± 0.19 | 0.41 ± 0.21 | 0.012 |
| Multifocality | 114 (32.9) | 28 (63.6) | < 0.001 |
| Bilaterality | 101 (29.2) | 24 (54.5) | 0.001 |
| ETE | 0.003 | ||
| No/minor | 252 (72.8) | 22 (50.0) | |
| Gross | 94 (27.2) | 22 (50.0) | |
| CLT | 92 (26.6) | 8 (18.2) | 0.274 |
| LVI | 16 (4.6) | 4 (9.1) | 0.263 |
| Stage | 0.406 | ||
| I | 255 (73.7) | 30 (68.2) | |
| II | 70 (20.2) | 9 (20.5) | |
| III | 21 (6.1) | 5 (11.4) | |
| Recurrence | 67 (19.4) | 17 (38.6) | 0.006 |
MRND modified lateral neck dissection, LN lymph node, ETE extrathyroidal extension, CLT chronic lymphocytic thyroiditis, LVI lymphovascular invasion
Univariate analysis of risk factors for recurrence
| Exp (B) | 95% CI for Exp (B) |
| |
|---|---|---|---|
| Age | |||
| ≤ 55 years | 1 | ||
| > 55 years | 1.138 | 0.713–1.816 | 0.589 |
| Sex | |||
| Female | 1 | ||
| Male | 1.037 | 0.653–1.648 | 0.877 |
| Main tumor size | |||
| ≤ 2 cm | 1 | ||
| > 2 cm | 1.689 | 1.068–2.671 | 0.025 |
| Skip metastasis | |||
| No | 1 | ||
| Yes | 0.696 | 0.392–1.235 | 0.215 |
| LN ratio (central) | |||
| ≤ 0.44 | 1 | ||
| > 0.44 | 2.492 | 1.508–4.118 | < 0.001 |
| LN ratio (lateral) | |||
| ≤ 0.29 | 1 | ||
| > 0.29 | 2.822 | 1.799–4.426 | < 0.001 |
| MRND type | |||
| Ipsilateral | 1 | ||
| Bilateral | 2.158 | 1.267–3.676 | 0.004 |
| Multifocality | |||
| No | 1 | ||
| Yes | 1.735 | 1.131–2.662 | 0.012 |
| Bilaterality | |||
| No | 1 | ||
| Yes | 1.514 | 0.981–2.337 | 0.061 |
| CLT | |||
| NO | 1 | ||
| Yes | 0.542 | 0.305–0.962 | 0.037 |
| ETE | |||
| No/minor | 1 | ||
| Gross | 1.583 | 1.022–2.453 | 0.040 |
| LVI | |||
| No | 1 | ||
| Yes | 1.097 | 0.444–2.708 | 0.841 |
| Stage | |||
| I | 1 | ||
| II | 0.952 | 0.548–1.654 | 0.862 |
| III | 1.740 | 0.863–3.509 | 0.122 |
CI confidence interval, LN lymph node, MRND modified radical neck dissection, CLT chronic lymphocytic thyroiditis, ETE extrathyroidal extension, LVI lymphovascular invasion
Fig. 1Kaplan-Meier curves according to CLN ratio (a), LLN ratio (b), and multifocality (c). CLN central neck lymph node, LLN lateral neck lymph node
Multivariate analysis of risk factors for recurrence
| Exp (B) | 95% CI for Exp (B) |
| |
|---|---|---|---|
| Main tumor size | |||
| ≤ 2 cm | 1 | ||
| > 2 cm | 1.480 | 0.931–2.355 | 0.098 |
| LN ratio (central) | |||
| ≤ 0.44 | 1 | ||
| > 0.44 | 1.890 | 1.124–3.178 | 0.016 |
| LN ratio(lateral) | |||
| ≤ 0.29 | 1 | ||
| > 0.29 | 2.351 | 1.477–3.743 | < 0.001 |
| Multifocality | |||
| No | 1 | ||
| Yes | 1.583 | 1.030–2.431 | 0.036 |
| CLT | |||
| No | 1 | ||
| yes | 0.644 | 0.362–1.149 | 0.136 |
| MRND type | |||
| Ipsilateral | 1 | ||
| Bilateral | 1.335 | 0.744–2.394 | 0.332 |
| ETE | |||
| No | 1 | ||
| Gross | 1.308 | 0.824–2.076 | 0.255 |
CI confidence interval, LN lymph node, CLT chronic lymphocytic thyroiditis, MRND modified radical neck dissection, ETE extrathyroidal extension
Postoperative complications
| Number (%) | |
|---|---|
| Hypoparathyroidism | |
| Transient | 16 (4.1) |
| Permanent | 3 (0.8) |
| Recurrent laryngeal nerve injury | |
| Transient | 23 (5.9) |
| Permanent | 14 (3.6) |
| Postoperative bleeding | 2 (0.5) |
| Chyle leakage | 2 (0.5) |